Cell & Gene 2024

06 - 08 November 2024 | London, UK

Join our premier event to unlock the potential of the CGT value chain, from discovery and development to successful commercialisation

Overview Cell Culture CGT Manufacturing Advanced Therapy Development

Explore Cell & Gene 2024: Advancing Future Insights in Cell & Gene Research

Featuring the 13th Annual Cell Culture Congress, 11th Annual Advanced Therapy Development Congress, and 10th Annual Cell & Gene Therapy Manufacturing Congress, this event is a dedicated platform for a comprehensive outlook on advancements in every step of the CGT value chain.

Cell & Gene 2024 has expanded into a three-day Congress, offering exclusive C- & Executive Level panel discussions on crucial topics within the CGT field. Additionally, we are thrilled to introduce our brand-new Innovation & Collaboration track, designed to spotlight pioneering presentations from emerging biotechs and spin-off companies.

13th Annual Cell Culture Congress

Connect and learn from experts working on the latest technological advancements and innovative strategies shaping the fields of cell culture, preclinical assessments, cell line engineering and bioprocessing. With presentations and interactive session ranging from developments in cell therapy quality control to cell line platform automation, attendees will find ample opportunities to benchmark their work and stay at the forefront of industry advancements.

  • Enjoy 3-days of networking opportunities to connect with leaders working across cell culture, bioprocessing, and cell line development
  • Explore strategies for cell culture optimisation and troubleshooting bottlenecks in cell line development through focused interactive sessions
  • Benchmark your work by attending presentations from leading companies, such as Bayer, AstraZeneca, Novartis, and more!

Agenda at a Glance


Day One & Day Two | Track 1: Cell Line Engineering & Development

Day One | Track 2 & Day Two | Track 3: Cell Culture & Cell Therapies Quality Control & Analysis

Day Two | Track 2: Upstream & Downstream Bioprocessing: Novel Technologies & Continuous Processing

Day Three | Track 1: Optimising Cell Culture Media & Models

10th Annual Cell & Gene Therapy Manufacturing Congress

In an era where knowledge-sharing and innovation drive advancements in the manufacturing, regulation, and commercialisation of advanced therapies, it's crucial to hear from leaders in the field of cell and gene therapy. Our conference provides a platform for these leaders to share insights into targeting increasingly challenging disease areas. Through presentations and case studies, attendees will gain actionable insights to enhance their manufacturing workflows, enabling scale-up, automation, and ensuring high quality throughout the entire supply chain process.

  • Dive into the CGT manufacturing landscape, with focused tracks addressing issues ranging from supply chain logistics to strategies for gene therapy manufacturing
  • Address pivotal questions in the CGT field, with featured panel discussions covering technologies for cell therapy scale-up & commercialisation 
  • Network with emerging CGT biotech and spinoff companies showcasing their pioneering work on our Innovation & Collaboration track

Agenda at a Glance


Day One | Track 5: Supply Chain & Logistics

Day Two | Track 5: Strategies for Gene Therapy Manufacturing & Production

Day Three | Track 5: Strategies for Cell Therapy Manufacturing & Production

11th Annual Advanced Therapy Development Congress

Join us as leading organizations present case studies on therapeutic breakthroughs, clinical protocols, regulatory frameworks, and market strategies, all aimed at introducing ground-breaking advanced therapies. Our presentations and interactive sessions will cover initial discovery to patient care, showcasing cutting-edge technologies and best practices across the CGT value chain.

  • Engage in specialized interactive sessions dissecting the regulatory and IP challenges pivotal to the progression of cell & gene therapies
  • Explore fresh tracks dedicated to the intricacies of CGT preclinical assessments, clinical trial design and development, as well as the journey of CGT commercialisation 
  • Hear from C- & Executive level leaders, hosting panel discussions on navigating the advanced therapy landscape & emerging modalities

Agenda at a Glance


Day One | Track 3: Gene Therapy Discovery & Development

Day One | Track 4: CGT Commercialisation

Day Two | Track 4: CGT Development

Day Three | Track 2: Preclinical CGT Assessments: Research & Development

Day Three | Track 3: CGT Clinical Development & Clinical Trial

Day Three | Track 4: iPSCs & Stem Cell Therapy Development

Nanostring

 

Relevant audience and topics. Great organisation and proactiveness from Oxford Global in making sure everything runs smoothly for exhibitors. 1-2-1 meetings are of highest value.


Business Development Manager
Nanostring

Sartorius

Well organised, excellent selection of talks with clearly structured themes. The event site was very pleasant with great service.

Field Application Specialist - BioAnalytics NE
Sartorius

Agilent

 

Excellent organisation and lots of relevant people attending. There was also great opportunities for face to face discussions. Excellent communication and flexibility to our needs.


Scientific Liaisons Manager
Agilent

GenScript

Love Oxford Global events! Well organised, great 1-2-1s and staff always on hand to help. There was a good relevance of attendees, with a mix of industry and client.


Advanced Services Specialist

GenScript

What to Expect

600

leading pharma, biotech, & academic delegates

30
hours of presentations, discussions & interactive content
13
hours of networking breaks, including speed networking & refreshments
230
hours of pre-arranged 1-2-1 meetings, facilitating business growth
What to Expect Engaging Thought Leadership
What to Expect Global Technological Showcase
What to Expect Networking Emphasis
What to Expect Innovative Poster Displays

Networking & knowledge-sharing is at the heart of what we do. Alongside the innovative programme, attendees can engage in a variety of event features and make the most of participation in a range of experiences

  • Engaging Thought Leadership

    Over 80 dynamic interactive discussions, roundtables, and presentations curated with insights from top industry leaders and experts
  • Global Technological Showcase

    An international exhibition showcasing cutting-edge technologies and services from leading providers in the scientific field.
  • Networking Emphasis

    Unparalleled networking opportunities, including speed networking sessions, a vibrant drinks reception, and informal gatherings to foster meaningful connections
  • Innovative Poster Displays

    Inspiring poster displays and presentations unveiling the latest breakthroughs from emerging biotech, pharma, and academic institutions

NEW FOR 2024!

Day One - Executive-Level Panel Discussions

These closed door sessions will include insights from key opinion leaders spearheading innovation in Cell and Gene Therapy. Places are limited — secure your spot now by selecting a session during registration.

Strategies For Navigating Evolving Regulatory Landscapes 

Moderated by:
Paolo Morgese,
Vice President Public Affairs Europe,
Alliance for Regenerative Medicine

Navigating The Advanced Therapy Landscape & Emerging Modalities

Moderated by:
Tim Allsopp,
Chief Technology Officer, Laverock Therapeutics

Exploring Autologous vs. Allogenic Therapies

Stay tuned for Moderator details

Mapping the Future of CGT Investment: Strategies for Funding and Reimbursement

Stay tuned for Moderator details

Key Themes for Cell & Gene 2024

The 2024 programme looks to cover salient themes across the CGT value chain. This year, discussion will feature focused sessions on autologous versus allogenic therapies, strategies to navigate regulatory hurdles, as well as exploring process development. Other key themes include cell culture optimisation, and the question of how to develop patient-centred clinical trials.

Across each track, key opinion leaders will come together with the shared goal of knowledge-sharing to advance cell and gene therapy development. Download our agenda to see more of the key themes Cell & Gene 2024 will cover!

Companies Represented Include

Biotech Innovation & Collaboration

Inspiring Tomorrow's Breakthroughs: Unleashing Innovation & Collaboration in Cell & Gene Research & Development

Join engaging presentations featured in our innovation and collaboration track running across day 2 and 3, inspiring growth and creating space for collaboration opportunities for all who attend. The core attendee mix includes early-stage and emerging biotech or (academic) spinoff companies developing their own platforms or technologies with fewer than 30 employees.  

The Innovation & Collaboration track will be comprising of 10-minute presentations and focused panel discussion sessions, encouraging networking, facilitating collaborations & showcasing emerging innovations in biomarkers discovery & development.

Featuring Attendees from Biotech and/or (Academic) Spinoff Companies Interested In:  

  • Seeking collaboration partners with pharma and solution providers 
  • Discovering new investment opportunities with pharma 
  • Learning about the latest industry trends & challenges  
  • Keeping updated with new innovations and technology solutions 
  • Showcasing their company profile to a targeted and engaged audience

2025 Young Scientist Awards (YSA) for Best Poster Presentation

The Cell & Gene Young Scientist Awards include the best poster presentation award and are intended to honour an outstanding individual performance for a scientific work by a PhD student, PostDoc or early career scientist. 

Please submit your poster presentation by no later than 20th December 2024 in the below category: 

  • Emerging Technologies  
  • Biomarkers in Therapeutics  
  • Biomarkers in Diagnostics  
  • Biomarkers in Clinical Trials & Precision Medicine  
  • Omics-Based Biomarker Discovery
  • Student (PhD), PostDoc or early career scientist under 35 years of age. Proof must be provided via an active student ID card or a copy of status
  • Applicants must be the first AND presenting author of the submitted paper and register for the meeting by 20th December 2024
  • ONLY ONE YSA submission per person will be accepted. If authors submit multiple abstracts for consideration for the YSA, only one abstract will be taken into consideration for the YSA

Applicants must follow the procedure as follows: 

  • Register and submit an abstract by 20th December 2024 using the registration link to the left on this page 
  • Once registered you will be provided with the online abstract submission form 
  • Prepare the poster or platform and present it (The poster presenter should be at the poster during all breaks.) 
  • The 3 winners with the highest scores will be announced at the Networking Drinks on the second day of the event 
  • The winners’ 10-minute oral presentations will take place during the networking drinks on day 2 

The platform or poster presentation will be evaluated by senior scientists (consisting of our speaking and steering group committee for the Biomarkers series) on the basis of originality of the approach and quality of the work (e.g. appropriate methodology, interpretation of results, conclusiveness). All participants will receive the scoring and comments after the annual meeting via email.

The 3 winners receiving the highest scores will be announced at the Networking Drinks on the Day 2 and will be given a trophy as well as £1,000 contribution towards travel costs. Oxford Global will also provide winners with PLUS Pass – 12 months access to our content platform providing access to on-demand presentations, exclusive reports and highlights. 

For further information contact help@oxfordglobal.com

Meet Our Expert Speakers

Cell & Gene 2024 again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative, data and industry outlooks.

Below are some of our featured speakers:

Anna Nowocin
Head of Flow Cytometry Standardisation,
MHRA
Ibon Garitaonandia
Chief Scientific Officer,
CellProthera
Julia Matilainen
Head of Patient Operations CGT,
Roche
Kyle Zingaro
Head of Gene Therapy Process Sciences,
UCB
Lindsay Davies
Chief Scientific Officer,
NextCell Pharma AB
Muhammad Akram
Senior Medical Director,
Legend Biotech
Paolo Morgese
Vice President Public Affairs Europe,
Alliance for Regenerative Medicine
Rolf Koehler
Associate director,
Novartis
Ruben Rizzi
Senior Vice President Global Regulatory Affairs,
BioNTech SE
Sarah Albon
Director,
Cambridge University Hospitals NHSFT
Theodora Weisz
Head of Patient Advocacy and Public Affairs EMEA,
Novartis
Tim Allsopp
Chief Technology Officer,
Laverock Therapeutics
Aisling McMahon
Professor of Law,
Maynooth University
Aline Miller
Principal Investigator, Professor of Biomolecular Engineering and Associate Dean for Business Engagement and Innovation,
University of Manchester
Anton Hutter
Partner, Patent Attorney,
Venner Shipley IP
Catia Andreassi
Director,
AviadoBio
Charlotte Wilding
Patent Attorney,
Venner Shipley
Chrysanthi Sitmalidou
Scientist II,
Orchard Therapeutics
Darius Widera
Professor of Stem Cell Biology and Regenerative Medicine,
University of Reading
Darren Nesbeth
Associate Professor,
UCL
Djordje Djordjevic
Co-founder + CEO,
Plurify
Dolores J. Schendel
Chief Scientific Officer,
Medigene AG
Dorothea Ledergerber
,
Independent
Elena Piletska
Associate Professor in Bioanalytical Chemistry,
University of Leicester
Eleonora Zucchelli
Senior Scientist,
Cell and Gene Therapy Catapult
Eli Gilsohn
VP, Intellectual Property,
Resolution Therapeutics
Emilie Gauthy
Head of CMC,
Celyad
Francesco Dazzi
Executive Medical Lead Cell Therapies,
AstraZeneca
Gabriel Kent
Analytical Development Scientist,
Resolution Therapeutics
Himansu Patel
Head of Quality Innovation,
Cell & Gene Therapy Catapult
James Carlson
Principal Safety Director ATMP Enablement,
Roche
Jas Uppal
Founder and CEO,
BQP Consultancy
John Garcia
Head of New Manufacturing Technologies,
UCL
John H Wolfe
Professor,
Child Hosp Philadelphia
Jose Bonafont Arago
Senior Scientist,
DanausGT
Kelly Evans
Senior Scientist,
AstraZeneca
Kirsty Crame
VP Clinical Strategy & Development,
Medigene AG
Klara Kulenkampff
Project Manager,
Bayer
Lucy Williams
Partner,
J A Kemp LLP
Luis Fernando Ayala Solares
Scientist - Cell Culture Media Development,
Merck Group
Luz Alonso-Crisostomo
Senior Scientist,
AstraZeneca
Mana Yen
Gene Therapies & Rare Diseases - Global Head of Health Systems,
Novartis Gene Therapies
Manuel Carrondo
Vice-President,
iBET
Marc Schneider
Director Product Supply Cell & Gene,
BioNTech
Marcel van Houten
Director Global Supply Chain,
orchrad-tx.com
Maria Luisa Giorello
Global Gene Therapy Platform Enablement Director,
Pfizer Ltd
Marina Tarunina
Research Director,
Plasticell Ltd
Matthew Gibson
Professor,
University of Manchester
Matthew Garner
Head of Intellectual Property,
Catapult
Menasheh Fogel
IT Head, Cell and Gene Therapy,
Bayer
Millie Fox
Senior Scientist,
AstraZeneca
Molly Stevens
John Black Professor of Bionanoscience,
University of Oxford
Monica Raimo
Sr. R&D Manager,
Glycostem Therapeutics
Nicolas Weber
Quality Team Leader,
Novartis Pharma
Nirai Govindasamy
Senior Scientist,
Bluu Seafood
Patrizia Ferretti
Professor of Regenerative Biology,
University College London
Philippe Henon
Chairman,
CellProthera SAS
Rahul Khetan
Venture Capital Associate,
UCB Ventures
Raiko Stephan
Gene & Cell Therapy Lead,
Novartis
Roshni Desai
Nonclinical Assessor,
MHRA
Ruth Faram
Co-Founder & Chief Scientific Officer,
HigherSteaks
Sakis Mantalaris
Professor,
Trinity College Dublin & NIBRT
Sam Goldsmith
Head of Commercialisation of Research & Investments,
CGT Catapult
Sarah Snykers
Director of Operations,
Legend Biotech
Sarah Howlett
Associate Director,
AstraZeneca
Sergey Piletsky
Professor in Bioanalytical Chemistry,
University of Leicester
Simon Chandler
CEO,
Rinri Therapeutics
Stephen Sullivan
Chief Operating Officer & Board Member,
iPSirius
Subhankar Mukhopadhyay
Senior Lecturer/Associate Professor,
King's College London
Sujith Sebastian
Viral Vector Hub Manager,
NHSBT
Terri Gaskell
Chief Technical Officer,
Rinri Therapeutics
Ulrich Dr. Rümenapp
Senior Biotech Program Lead,
Bayer AG
Uwe Buecheler
Senior Advisor - Biopharmaceuicals,
Boehringer Ingelheim
Vicki Coutinho
Managing Director & Consultant,
Geni Consulting
Wonjong Si
Associate Director, Cell Therapy Platform Process,
Bayer
Xavier Fontana
Principal Scientist,
Adaptimmune
Yen Choo
Founder & Chairman; Associate Professor of Stem Cell Science and Regenerative Medicine,
Plasticell; Lee Kong Chian School of Medicine Science

Interested in Sponsoring?

Oxford Global’s range of sponsorship opportunities are highly effective in enabling market immersion and visibility, with direct access to clients and potential customers.

Learn more

Latest Resources

Is Single-Use Bioprocessing the Way Forward?

Danish company Novo Holdings has acquired a majority stake in the Austrian-based company Single Use Support, marking a critical stride towards the wider adoption of single-use bioprocessing tools.

Implementing Process Analytical Technology into Cell and Gene Therapy Manufacturing

A recent study shows that a novel refractometry-based PAT system monitors metabolic activity during CGT production, revealing insights into optimising bioprocesses.

In Conversation with Stephen Sullivan, COO of iPSirius

Cell & Gene 2024 Conference Producer Anya Chuykov met with Stephen Sullivan, COO of iPSirius, to discuss the advancements being made by iPSirius, and their unique proprietary technology working to treat aggressive forms of cancer.

UNIVERCell: Engineering Red Blood Cells for Targeted Therapy

Scarlet Therapeutics uses genetic manipulation of red blood cells to carry a higher load of therapeutic proteins to help treat rare metabolic diseases.

Cell Therapy for Solid Tumors: An Innovative Approach to Cancer Treatment

Cell therapy for solid tumours is an innovative cancer treatment that uses a patient's own immune cells or donor cells to fight cancer, but its effectiveness varies by tumour type and patient's immune system. Although it offers new hope, it poses risks such as cytokine release syndrome and neurotoxicity. Recent advancements have led to better targeting, combination therapies, and next-generation treatments, with future research aimed at improving safety, effectiveness, and accessibility, potentially revolutionising cancer care.

Advancing Melanoma Treatment: The FDA Gives Lifileucel The Greenlight in Historic Cell & Gene Therapy Breakthrough

The Food and Drug Administration (FDA) approved lifileucel, a one-of-a-kind T-cell therapy developed by Iovance Biotherapeutics for treating melanoma.

Plan Your Visit

Novotel London West

1 Shortlands,
Hammersmith International Ctre,
London, W6 8DR

Just minutes from three of London's main tube lines (Piccadilly, District and Hammersmith & City) and located in the heart of Hammersmith; Novotel London West is ideally located for trips to Westfield London, Harrods & Kensington High Street. Also conveniently located to Heathrow Airport with excellent road and rail links to the rest of the UK. This large and modern hotel offers on-site parking (chargeable), fitness suite and complimentary Wi-Fi throughout.

By Air

London Heathrow Airport - Novotel London West is accessible from Heathrow via the Underground on the Piccadilly Line - fares cost around £5 into Central London. A taxi from the airport will take approximately 20 minutes and will cost around £30 - £40.

London Gatwick Airport - The Gatwick Express runs every 15 mins - take it to Victoria station, and then get the District line to Hammersmith (about 15 mins). A taxi from the airport will take around 60 mins and cost between £65 - £80.

By Underground & Bus

Hammersmith Underground Station is adjacent to the hotel (3 minutes walk) with access to the Piccadilly, District and Hammersmith & City Lines. When exiting Hammersmith station, turn right and walk across the bus station. Cross over the roads using the island and keep on the right-hand side of Hammersmith Road. Continuing walking for 2 mins, and the hotel is accessible via stone steps.

For buses in central London, take route numbers 9 and 10. The main coach station (London Hammersmith) is 3 minutes walk away.

By Rail

The closest National Rail train station is Kensington Olympia (20 minutes walk).

By Car

Leave the A4 at the Hammersmith turning and proceed along Hammersmith Bridge Road to the large roundabout underneath the flyover. Take the fifth exit off the roundabout. Then turn left into Shortlands - the main hotel entrance and parking will be on your left-hand side.

Parking

Novotel London West offers over 240 on-site car parking spaces (charged per hour for residents parking). For further information including a map and full directions, please visit: www.novotel.com/gb/hotel-0737-novotel-london-west/index.shtml

Oxford Global have secured a number of bedrooms at Novotel London West at a reduced rate:

 

Tuesday 5th November 2024 – £190, breakfast included

Wednesday 6th November 2024 – £190, breakfast included

Thursday 7th November 2024 – £190, breakfast included


Should you wish to book a room, please 
click here.

 

The final cut-off date to book bedrooms is Tuesday 15th November 2024 – any bookings after this date are subject to availability and rates. Please note, that any cancellations within 14 days prior to arrival are subject to cancellation charges.

 

Additionally, we kindly remind all attendees to only book their accommodation if they are registered for the event. This ensures that accommodations are available for those who have officially secured their attendance.

We are closely monitoring the official guidance from health authorities, local governments, and the World Health Organization in order to support the health and well-being of our global community. The health and safety of our staff, customers and clients remains our number one priority.

As we continue to move forward with hosting our events in-person in 2024, we’ve added a series of Health & Safety guidelines and precautions in order to prepare for event safety. We carry out risk assessments for all our events to evaluate fundamental considerations and how to cover multiple risk scenarios.

Oxford Global has learned that third-party companies (recently EHotel Services, Business Travel Management/btravelmanagement and Exhibitors Hotel Reservations Services) are targeting conference attendees with a fraudulent hotel booking scheme.

Please note that none of these third-party companies are associated with Oxford Global in any way, nor have Oxford Global authorised them to use their names or trademarks on information they send out to attendees.

If you are contacted by a third-party company by phone or email using Oxford Global’s name or the name of Cell & Gene 2024 and offering accommodation services, we urge exhibitors and attendees to proceed with extreme caution before signing anything sent by these companies or entering into any conversation or replying to any emails sent from these third-party companies.

Register Your Interest

Submit your details and a member of our team will be in touch